Baseline characteristics of 18 patients treated with Nivo + EPOCH
| Baseline characteristics . | N = 18 (%) . |
|---|---|
| Subtype | |
| Peripheral T-cell lymphoma NOS | 7 (38.9%) |
| T-cell lymphomas with a FH phenotype | 6 (33%) |
| Primary cutaneous γ/δ T-cell lymphoma | 2 (11.1%) |
| Anaplastic large cell lymphoma, ALK- | 2 (11.1%) |
| Subcutaneous panniculitis like T-cell lymphoma | 1 (5.6%) |
| CD30 expression >10%∗ | 2 (11%) |
| EBV-associated† | 6 (33%) |
| Age | |
| Median | 66 |
| Range | 43-77 |
| Sex, M | 10 (58.8%) |
| ECOG PS | |
| 0-1 | 7 (38.9%) |
| 2 | 11 (61.1%) |
| Stage | |
| III | 1 (5.6%); |
| IV | 17 (94.4%) |
| LDH, greater than normal | 10 (55.6%) |
| Extranodal sites, 2 or more | 7 (41.2%) |
| IPI | |
| Low (0-1) | 3 (17%) |
| Intermediate (2-3) | 6 (33%) |
| High (4-5) | 9 (50%) |
| Baseline characteristics . | N = 18 (%) . |
|---|---|
| Subtype | |
| Peripheral T-cell lymphoma NOS | 7 (38.9%) |
| T-cell lymphomas with a FH phenotype | 6 (33%) |
| Primary cutaneous γ/δ T-cell lymphoma | 2 (11.1%) |
| Anaplastic large cell lymphoma, ALK- | 2 (11.1%) |
| Subcutaneous panniculitis like T-cell lymphoma | 1 (5.6%) |
| CD30 expression >10%∗ | 2 (11%) |
| EBV-associated† | 6 (33%) |
| Age | |
| Median | 66 |
| Range | 43-77 |
| Sex, M | 10 (58.8%) |
| ECOG PS | |
| 0-1 | 7 (38.9%) |
| 2 | 11 (61.1%) |
| Stage | |
| III | 1 (5.6%); |
| IV | 17 (94.4%) |
| LDH, greater than normal | 10 (55.6%) |
| Extranodal sites, 2 or more | 7 (41.2%) |
| IPI | |
| Low (0-1) | 3 (17%) |
| Intermediate (2-3) | 6 (33%) |
| High (4-5) | 9 (50%) |
FH, follicular helper; NOS, not otherwise specified; M, male; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IPI, international prognostic indices; among the peripheral T-cell lymphomas with a follicular helper phenotype, 4 were angioimmunoblastic T-cell lymphomas and 2 were FH TCL NOS. The subcutaneous panniculitis like T-cell lymphoma did not respond to methotrexate before enrollment.
Only the 2 ALCLs had >10% expression.
Epstein-Barr virus association or positivity was defined as any EBER positivity or elevated viral load measured using polymerase chain reaction.